Navigation Links
Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Date:5/23/2013

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML.  This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.

"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging.  Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics. 

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug.  Its pipeline of validated targets treat diseases therapeutically and prophylactically.  By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase Therapeutics is also developing a broad-spectrum antiviral specific for enveloped viruses, opening new avenues for vaccine development and biodefense. For more information, please visit the Company's website at www.inhibikase.com.

For Further Information Contact:

Milton H. Werner , PhD
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831 (m)
mhwerner@inhibikase.com


'/>"/>
SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
2. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
3. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
4. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Novelos Therapeutics Provides Product Pipeline Update
10. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
11. Mast Therapeutics Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of ... offering. ... report forecasts the global optical transceiver market to grow at a ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the shipment of optical ...
(Date:12/9/2016)...  Harmar Mobility, LLC announced today that Steven E. Dawson has been ... of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing ... of industries. He brings to the company deep operational and leadership expertise, ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a ... to address severe, rare diseases, today announced that senior management will ... Success Healthcare Conference at the InterContinental Barclay Hotel in ... 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma is engaged ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
Breaking Medicine News(10 mins):